Expand NRIX Menu
NRIX MENU

NRIX Latest Press Releases

-- May 14, 2026 --

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting Globe Newswire 4:05 PM

-- May 13, 2026 --

Nurix Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- May 12, 2026 --

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress Globe Newswire 4:05 PM

-- April 22, 2026 --

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 Globe Newswire 7:00 AM

-- April 8, 2026 --

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Globe Newswire 6:00 AM

-- April 7, 2026 --

Nurix Therapeutics to Participate in Upcoming Investor Conference Globe Newswire 7:00 AM

-- March 23, 2026 --

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting Globe Newswire 4:05 PM

-- January 28, 2026 --

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update Globe Newswire 4:01 PM

-- January 12, 2026 --

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases Globe Newswire 7:00 AM

-- January 5, 2026 --

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes